The IRA and State PDABs are Taking Effect – What's Next?

Join us in Boston for an evening of lively debates on what the Inflation Reduction Act (IRA) and state Prescription Drug Affordability Boards (PDABs) mean for the biopharma industry and what will happen next.

During this in-person event, our debaters will discuss key questions surrounding some of the significant policy shifts shaping the future of drug development:

• Was the first round of IRA price negotiations a success, and what are the long-term implications?
• What is the real impact of state-level PDABs on drug pricing and access across the US?

Attendees will gain valuable strategies and perspectives from our expert debaters, helping predict what might be next for the IRA and PDABs and what this might mean for future drug launches in the evolving regulatory landscape.

Meet Our Expert Speakers

Jon Campbell, PhD, MS, is the Chief Science Officer (CSO) of the National Pharmaceutical Council (NPC), which sponsors and conducts research on health policy issues related to the development and use of innovative biopharmaceuticals to improve the health of patients. As a researcher and advocate for improving the U.S. healthcare system through sustainable access and biopharmaceutical innovation, Dr. Campbell is dedicated to conducting research that helps decision-makers understand the tradeoffs and consequences of health policies that impact patient access to treatments and the ecosystem of biopharmaceutical innovation.

Paul Jeffrey, PharmD, is an independent consultant specializing in Medicaid Pharmacy, formulary development and delivery, value-based care and value-based therapeutics contracts with a focus on cell and gene therapy and prescription digital therapeutics. Dr. Jeffrey is recently retired as Senior Director of Pharmacy in the Office of Clinical Affairs at the UMass Chan Medical School (UMMS)/Commonwealth Medicine. In this capacity, he was Senior Director of Pharmacy for MassHealth and was responsible for the state’s Pharmacy benefit for approximately 1.2 million of MassHealth’s 2 million members and a budget of $2.3 billion; and negotiated supplemental rebate agreements of $300+ million.

We invite the the Greater Boston biopharma community to partake in these critical debates, ask questions, and share their own insights. Refreshments and networking time are included with registration.